ImmuCell Corporation
ICCC
$5.25
$0.255.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.49% | 21.75% | 28.29% | 51.63% | 46.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.49% | 21.75% | 28.29% | 51.63% | 46.37% |
| Cost of Revenue | -5.60% | 3.82% | 20.17% | 38.77% | 40.10% |
| Gross Profit | 70.78% | 67.15% | 47.19% | 89.89% | 64.43% |
| SG&A Expenses | 8.18% | 3.90% | 14.10% | 8.81% | -2.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.80% | -1.64% | 10.47% | 22.18% | 20.39% |
| Operating Income | 199.91% | 163.95% | 105.65% | 76.38% | 52.70% |
| Income Before Tax | 161.43% | 143.83% | 93.29% | 62.80% | 39.57% |
| Income Tax Expenses | 175.00% | 170.73% | 144.19% | 120.00% | 10.64% |
| Earnings from Continuing Operations | 160.98% | 143.51% | 93.03% | 62.65% | 39.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 160.98% | 143.51% | 93.03% | 62.65% | 39.53% |
| EBIT | 199.91% | 163.95% | 105.65% | 76.38% | 52.70% |
| EBITDA | 11,009.24% | 862.91% | 635.69% | 158.07% | 98.42% |
| EPS Basic | 153.32% | 136.16% | 87.42% | 62.31% | 40.31% |
| Normalized Basic EPS | 163.92% | 137.67% | 87.21% | 67.86% | 46.96% |
| EPS Diluted | 150.64% | 134.48% | 85.84% | 61.08% | 38.77% |
| Normalized Diluted EPS | 163.92% | 137.67% | 87.21% | 67.86% | 46.96% |
| Average Basic Shares Outstanding | 14.35% | 13.05% | 9.34% | 5.39% | 1.57% |
| Average Diluted Shares Outstanding | 14.35% | 13.05% | 9.34% | 5.39% | 1.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |